Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A peptide vaccine preparation, containing recombinant human epidermal growth factor (rEGF) linked to the Neisseria meningitidis-derived recombinant immunogenic carrier protein P64k (rP64k) and mixed with the immunoadjuvant Montanide ISA 51, with potential active immunotherapy activity. Recombinant human EGF-rP64K/Montanide ISA 51 vaccine may trigger a humoral immune response against vaccine rEGF and rP64K and, so, against endogenous EGF. Antibody-mediated inhibition of endogenous EGF binding to its receptor, epithelial growth factor receptor (EGFR), may result in the inhibition of tumor cell proliferation.

**Synonyms:** - CIMAvax EGF - CIMAvax Epidermal Growth Factor Vaccine - CIMAvax-EGF - Center of Molecular Immunology (CIMA) Epidermal Growth Factor (EGF) Vaccine - Center of Molecular Immunology Epidermal Growth Factor Vaccine - CimaVax - CimaVax Vaccine - Cimavax - Recombinant Human EGF-P64K/Montanide Vaccine